Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

and unpredictability inherent in our industry, while at the same time meeting or exceeding expectations for more than four consecutive years and consistently delivering strong results. With three quarters of the year completed, we are tightening our 2011 adjusted diluted EPS guidance range to $1.98 to $2.02, and are retaining our midpoint of $2.00 per share, excluding any potential contribution from the generic version of Doryx®, 150 mg. While this product is currently the subject of a preliminary injunction, the Federal Circuit has granted an expedited appeal with oral arguments scheduled for November 22, 2011. We are confident that we will prevail in the litigation and believe generic Doryx now represents a potential upside opportunity in the current year. Looking ahead, we reaffirm our compound annual growth targets of 15% top-line and 20% bottom-line, culminating in projected adjusted diluted EPS of $2.75 by the end of 2013."

Financial SummaryTotal third party revenues for the quarter ended September 30, 2011, increased $220.6 million, or 16.3% to $1.58 billion from $1.36 billion in the comparable prior year period. Total revenues include both net revenues and other revenues from third parties. Third party net revenues for the current quarter were $1.57 billion compared to $1.34 billion for the prior year quarter, representing an increase of $227.3 million, or 16.9%. Other third party revenues for the current quarter were $3.4 million compared to $10.1 million in the prior year quarter, a decrease of $6.7 million. Revenues in the current quarter were favorably impacted by the effect of foreign currency translation, generally reflecting a weaker U.S. dollar as compared to the currencies of the other major markets in which Mylan operates.  Translating third party net revenues for the current quarter at prior year comparative period exchange rates would have resulted in year-over-year growth in third party net revenues, excluding foreign curren
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Pittcon Organizing ... of Food Safety Tech , an e-Journal and producer ... an agreement for the second year for the co-location of ... 2014. The partnership provides that the registration fee to attend ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Nov. 10, 2010 Celsion Corporation (Nasdaq: ... that is leveraging its heat sensitive liposomal platform to ... announced that it has changed  the date and time ... Veteran,s Day Holiday on November 11, 2010.  The SEC,s ...
... Biodesix Inc. announced today that the company has ... existing investors. The Series C round, which included 5 ... company,s first product VeriStrat®, a serum proteomic test that ... lung cancer (NSCLC). Existing shareholders of the company provided ...
... StemCellRegenMed, Inc. announces that a new stem cell gene ... month old child with Tay-Sachs disease on November 2, 2010. ... parents of Jewish heritage and in very rare cases families ... U.S.A. The children appear normal at birth but about six ...
Cached Biology Technology:Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010 2Biodesix Completes Series C Financing and Receives Grant 2Biodesix Completes Series C Financing and Receives Grant 3Tay-Sachs Disease Stem Cell Gene Enzyme Treatment 2
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... material -- in particular, dog fecal material -- may constitute ... wintertime air, says a new University of Colorado Boulder study. ... Midwestern cities in the experiment, two cities had significant quantities ... being the most likely source. "We found unexpectedly ...
... life-saving to have a warning sign before a structural system ... size, having a sign that,s easy to read is a challenge. ... University of Pennsylvania and Duke University bioengineers and chemists, such warning ... The study was conducted by professor Daniel Hammer ...
... Women and men experience pain, particularly chronic pain, ... pain also differs between women and men. While it ... analgesics are more effective in women than men, the ... Narcotic analgesics decrease pain by activating opioid receptors, which ...
Cached Biology News:New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 2New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 3Penn molecular scientists develop color-changing stress sensor 2Penn molecular scientists develop color-changing stress sensor 3SUNY Downstate researchers identify possible new targets for treating pain in women 2
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... for determining the absolute count of CD34+ ... peripheral blood samples, and leukapheresis samples. These ... cell count and a total CD45 (leucocyte) ... use in the BD Procount progenitor cell ...
... 2HCl White to off-white ... inhibitor. Inhibits translation by causing premature ... DNA fragmentation in thymocytes and in ... ≥98% by TLC. Soluble in ...
... NOBLE BSA-Free Stabilizer is a bovine ... It is an aqueous solution ... a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... a combination of 0.02% methylisothiazolone and ...
Biology Products: